Key points from article :
65 years and older people using aspirin regularly show a 15% reduction in all-cause mortality.
Contradicts ASPREE trial where using aspirin exhibited a small increase in mortality.
Benefits and risks vary with patient characteristics, such as whether or not a patient is overweight.
Prophylactic aspirin use has a protective association against cancer mortality.
But needs to consider age and risk of bleeding before recommending aspirin for cancer prevention.
Research by National Cancer Institute, published in JAMA Network Open.
